Performance evaluation of the point-of-care SAMBA II SARS-CoV-2 Test for detection of SARS-CoV-2

Sonny M Assennato[a], Allyson V Ritchie[a], Cesar Nadala[b], Neha Goel[a], Hongyi Zhang[c], Rawlings Datir[d], Ravindra K Gupta[e,f], Martin D Curran[c]*, Helen H Lee[a,b]*#

* Curran and Lee contributed equally

a. Diagnostics for the Real World EU Ltd., Chesterford Research Park, Great Chesterford, UK

b. Diagnostics for the Real World Ltd., San Jose, USA

c. Public Health England, Clinical Microbiology and Public Health Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

d. Division of Infection and Immunity, University College London, London, UK

e. Department of Medicine, University of Cambridge, Cambridge, UK

f. Africa Health Research Institute, Durban, South Africa

Running Title: SAMBA II SARS-CoV-2 analytical and clinical evaluation

Address correspondence to Dr Helen H Lee, email: hl207@cam.ac.uk

Key words: SAMBA II, SARS-CoV-2, point-of-care, COVID-19

Abstract

Nucleic acid amplification for the detection of SARS-CoV-2 RNA in respiratory samples is the standard method for diagnosis. These tests are centralised and therefore turnaround times can be 2-5 days. Point-of-care testing with rapid turnaround times would allow more effective triage in settings where patient management and infection control decisions need to be made rapidly.

Inclusivity and specificity of the SAMBA II SARS-CoV-2 assay was determined by *in silico* analyses of the primers and probes. Analytical and clinical sensitivity and specificity of the SAMBA II SARS-CoV-2 Test was evaluated for analytical sensitivity and specificity. Clinical performance was evaluated in residual clinical samples compared to the Public Health England reference tests.

The limit of detection of the SAMBA II SARS-CoV-2 Test is 250 cp/mL and is specific for detection of 2 regions of the SARS-CoV-2 genome. The clinical sensitivity was evaluated in 172 clinical samples provided by Public Health England, Cambridge, which showed a sensitivity of 98.9% (95% CI 94.03-99.97%), specificity of 100% (95% CI 95.55-100%), PPV of 100% and NPV of 98.78% (92.02-99.82%) compared to testing by Public Health England (PHE). SAMBA detected 3 positive samples that were initially negative by PHE.

The data shows that the SAMBA II SARS-CoV-2 Test performs equivalently to the centralised testing methods with a much quicker turnaround time. Point of care testing, such as SAMBA, should enable rapid patient management and effective implementation of infection control measures.

Introduction

The SARS-CoV-2 was first reported in Wuhan, China, in early December 2019 and is the causative agent of coronavirus disease 19 (COVID-19) [1]. It has since spread to over 188 countries/regions around the world [2], causing 317,234 deaths [3]. It was declared a pandemic by the World Health Organisation on the 11th of March 2020 [4]. In Europe, the country with the highest number of deaths is UK, which as of the 17th of May has had 243,694 lab-confirmed cases and 34,636 deaths in all settings [5].

Nucleic acid testing is essential for early diagnosis of SARS-CoV-2 infection as antibody response is often not detected until 7-10 post onset of symptoms [6]. Upper respiratory tract (URT) specimens such as nose and throat swabs generally have high SARS-CoV-2 viral loads upon symptom onset [7]. The standard diagnostic test for SARS-CoV-2 in the UK is done by real-time RT-PCR of the RdRp gene [8], from a combined throat and nose swab sample. The UK has dramatically scaled up testing from 5,000 tests per day in March 2020 to 100,000 tests per day by the end of April. Although this test has good accuracy, the samples must be transported to centralized testing laboratories and batched for processing, which leads to turnaround times of around 48 hours or more. This means treatment of severely ill patients may be suboptimal when other causative pathogens are in the differential diagnosis and those requiring admission or triage with possible COVID-19 maybe unnecessarily isolated or inappropriately cohorted in a COVID-19 ward. This causes obvious bottlenecks in addition to the sheer number of samples that require processing; at present hospital and regional laboratories are at full capacity and a rapid point of care (POC) testing is required.

The SAMBA II nucleic acid testing system was originally designed for HIV testing in POC and resource-limited settings, with CE-marked products for early infant diagnosis

76 [9,10] and viral load monitoring [11-13]. Since 2017, SAMBA HIV tests have been
77 implemented in Uganda, Malawi, Zimbabwe and Central African Republic. The
78 SAMBA II SARS-CoV-2 Test system has now been developed to specifically detect
79 the presence of the novel coronavirus, SARS-CoV-2, in nose and throat swab samples
80 run on the SAMBA II instrument. Test results are available within 77-93 minutes.
81 We have here assessed the analytical and clinical performance of the SAMBA II
82 SARS-CoV-2 Test using panels and clinical samples.
83

84 **Materials and Methods**

85 **SAMBA sample preparation, amplification, and detection**

86 For the SAMBA II system, sample preparation, amplification, and detection as well as
87 reading and interpretation of the results are fully automated. The test is carried out in
88 the SAMBA II Assay Module under the control of the SAMBA II Tablet Module as
89 previously described for HIV [9-12], according to the manufacturer's instructions for
90 use. Nose and throat swab samples are preferably resuspended in 2 mL of SAMBA
91 SCoV buffer but the system can be used with viral transport medium (VTM) if the
92 sample is diluted 1:2 with SCoV buffer prior to processing. The input volume for the
93 SAMBA test is 300 μl of which 250 μl is used by the SAMBA II machine as input into
94 the sample preparation. The SAMBA II SARS-CoV-2 Test specifically amplifies and
95 detects two regions of the SARS-CoV-2 genome in the ORF1ab (region 1) and
96 nucleoprotein (region 2), reported as two distinct lines on the test strip. A third line on
97 the test strip, the internal control, is present to control for false negatives caused by
98 instrument/reagent problems or inhibition. The presence of one or both test lines
99 indicates a positive result. The presence of just the internal control line indicates a
100 negative result.

101 **Virus inactivation in SAMBA SCoV buffer**

102 SAMBA SCoV buffer, containing Triton x100, is provided with the SAMBA II SARS-
103 CoV-2 Test for sample collection of the nose and throat swabs. Single round of VSV-
104 G pseudotyped lentiviruses were produced by transfecting HEK-293T cells in a 3-
105 plasmid transfection system (HIV Gag-pol expresser under a CMV promoter,
106 luciferase genome reporter and VSV-g envelope) as previously described [14]. Virus
107 supernatant was harvested after 24 hours and filtered. Fifty (50) µL
108 of pseudovirus preparation was added to increasing dilutions of SAMBA SCoV Buffer
109 in duplicates and incubated at room temperature for 5 minutes. 100µL of the virus-
110 reagent prep was then used to infect 1.0×10^6 TZMbl target cells per well in a 96-well
111 plate and incubated at 37ºC, 5% CO_2. Forty-eight (48) hours post-infection, luciferase
112 expression was measured using SteadyGlo and a Glomax Luminometer (both
113 Promega).

114

115 ***In silico* inclusivity analysis**

116 The SAMBA-SARS-CoV-2 primers and probes for Orf1ab and N regions were
117 individually evaluated using *in-silico* analysis with respect to 157 SARS-CoV-2
118 sequences in the NCBI database.

119

120 ***In silico* specificity analysis**

121 *In silico* analysis for possible cross-reactions with related human Coronaviruses
122 (Human coronavirus 229E, Human coronavirus OC43, Human coronavirus HKU1,
123 Human coronavirus NL63, SARS-coronavirus and MERS-coronavirus) was conducted
124 by mapping primers in the SAMBA II SARS-CoV-2 Test individually to the sequences
125 downloaded from the NCBI database.

126 An *in silico* analysis for possible cross-reactions with other high-priority organisms was
127 conducted by carrying out a blastn search for each of the SAMBA primers and probes
128 against NCBI databases and retrieving all sequences with homologies > 80%.
129

130 **Panels and samples**

131 Panel members for determination of the limit of detection (LOD) were prepared by
132 making serial dilutions of SARS-CoV-2 RNA from strain 2019-nCoV/Italy-INMI1 from
133 EVAg (code number: 008N-03894) in pooled negative combined nose and throat
134 swab samples to target concentrations of 750, 500, 250, 200, 150 and 100
135 copies/mL.
136 A Coronavirus RNA specificity panel containing hCoV-NL63, hCoV-229E, hCoV-
137 OC43, MERS-CoV and SARS-CoV HKU339849 were sourced from EVAg (code
138 number 011N-03868). RNA samples from this panel were tested at >100,000 cp/test
139 in the SAMBA II test to determine specificity against other human Coronaviruses.
140

141 **Contrived clinical samples**

142 Combined nose and throat swabs were collected from 35 presumed negative
143 individuals using FLOQSwabs (Copan, Italy) and SAMBA SCoV buffer. Thirty
144 contrived positive clinical samples were prepared by spiking known concentrations of
145 SARS-CoV-2 RNA strain 2019-nCoV/Italy-INMI1 (EVAg, Italy) into individual negative
146 specimens to produce final concentrations of 1x LoD (n=3), 2x LoD (n=17), 3x LoD
147 (n=5), 5x LoD (n=3) and 100x LoD (n=2).
148
149
150

151 **Clinical evaluation**

152 The clinical performance of the SAMBA II SARS-CoV-2 Test was further evaluated
153 retrospectively with 172 residual blinded combined nose and throat swab samples
154 from Public Health England (PHE), Cambridge laboratory. These residual samples
155 were from symptomatic individuals with suspected Covid-19 from around the East of
156 England region sent for routine laboratory diagnosis and provided as VTM diluted 1:2
157 with SAMBA SCoV buffer. In total 172 samples were tested by the SAMBA II SARS-
158 CoV-2 Test and results were compared to the Cambridge RdRp gene (Wuhan) assay
159 on the Rotor gene Q real-time PCR assay routinely used by Public Health England
160 Cambridge Laboratory based on the publication by Sridhar et al., 2020 [15]. Results
161 are expressed as positive or negative with a Ct cut off of 36 for positive results.
162 Samples were also tested with the PHE Colindale (Reference Laboratory) assay,
163 based on the publication by Corman et al, 2020 [8], which amplifies a different region
164 of the RdRp gene.

165 For LOD, we used SARS-CoV-2 RNA quantified in cp/mL but in the clinical samples,
166 SAMBA II results were compared to real-time PCR results expressed as Ct number
167 (number of cycles). By systematically testing serial dilutions of samples calibrated in
168 cp/mLby the PHE test a correspondence curve was drawn showing for instance that
169 25 Ct corresponded to 100,000 cp/mL and 30 Ct to 1,000 cp/mL. The curve obtained
170 is added as supplementary information.

171

172 **Research Ethics**

173 Surplus samples obtained from patients known to be symptomatic for COVID-19 and
174 submitted to the Public Health England Cambridge Laboratory for routine testing were
175 retrieved before being discarded. These samples were rendered anonymous and

176 provided blinded for the purpose of test validation. Public Health England and NHS
177 Research Ethics Committee have permitted the use of residual samples in this
178 manner, strictly for the purpose of diagnostic assay validation [16]. The evaluation was
179 carried out in accordance with The Use of Human Organs and Tissue act [17].
180

181 **Results**

182 **Viral inactivation by SAMBA SCoV collection buffer**

183 Due to the highly infectious nature of SARS-CoV-2, a proprietary buffer which has a
184 low pH and a strong detergent was developed for the SAMBA SARS-CoV-2 Test for
185 sample collection. The ability of the SAMBA SCoV Buffer to inactivate pseudoviruses
186 was assessed by incubating pseudoviruses with increasing dilutions of
187 SAMBA SCoV Buffer in duplicates at room temperature for 5 minutes. Forty-eight (48)
188 hours post-infection, luciferase expression was measured. Figure 1 shows the plot of
189 $\log_{10}$ relative light units (RLU) of luciferase expression vs concentration of
190 SAMBA SCoV Buffer containing Triton X100. Results show that luciferase activity was
191 insignificant up to 1:128 dilution of the SAMBA SCoV Buffer, indicating that
192 the pseudovirus was inactivated after 5-minute exposure at room temperature (Figure
193 1). For the SAMBA II Test, a 10-minute soaking of the swab in the
194 SAMBA SCoV Buffer is recommended.
195

196 **Limit of detection**

197 The limit of detection (LOD) of the SAMBA II SARS-CoV-2 Test was determined using
198 serial dilutions of SARS-CoV-2 RNA in pooled negative combined nose and throat
199 swab samples. The initial LOD was determined by testing 6 levels at target
200 concentrations of 750, 500, 250, 200, 150 and 100 copies/mL. Each panel member

201 was tested in replicates of 3 (Table 1). The final LOD was confirmed by testing 250
202 copies/mL in replicates of 20, of which all were detected. The results are summarized
203 in Table 1. Therefore, the claimed LOD of the SAMBA II SARS-CoV-2 Test is 250
204 cp/mL.
205
206 **Inclusivity**
207 The SAMBA II SARS-CoV-2 Test primers and probes for Target 1 (Orf 1ab) had 100%
208 match to all but one available SARS-CoV-2 sequence for this region in the NCBI
209 database (n=157). For this one sequence, a single nucleotide mismatch was found
210 that maps to the capture probe with no predicted impact on the assay performance.
211 The primers and probes for Target 2 (N) had 100% identity to all available SARS-CoV-
212 2 sequences for this region in the NCBI database (n=157).
213
214 **Specificity analysis**
215 *In silico* analysis for possible cross-reactions with related human coronaviruses
216 (Human coronavirus 229E, Human coronavirus OC43, Human coronavirus HKU1,
217 Human coronavirus NL63, SARS-coronavirus and MERS-coronavirus) concluded that
218 none of the SAMBA primers had >80% homology to the organisms listed. In addition
219 to *in silico* analysis, the SAMBA II SARS-CoV-2 Test was evaluated for specificity by
220 using >100,000 cp/test of hCoV-NI63, hCoV-229E, hCoV-OC43, MERS-CoV and
221 SARS-CoV RNA as target in the assay. All samples gave negative results in SAMBA
222 showing that both the Orf1ab and N primers and probes in the SAMBA II SARS-CoV-
223 2 were specific.
224 An *in silico* analysis for possible cross-reactions with other high-priority organisms
225 showed that only one SAMBA probe (N region) had greater than 80% homology (81%)

226 to one of the high priority organisms (*Pneumocystis jirovecii* [PJP]). This marginal
227 homology would not impact the performance of the test because the other primers and
228 probes have no homology to *P. jirovecii*. This homology would not be able to compete
229 with 100% homology of the SARS-CoV-2 amplicon to the capture probe.
230
231 **Contrived clinical specimens**
232 Positive (n=30) and negative (n=35) swab samples were contrived from individual
233 nose and throat swab samples collected from 35 individuals and tested with the
234 SAMBA II SARS-CoV-2 Test. Spiked positive samples were tested at 1x LOD (n=3),
235 2x LOD (n=17), 3x LOD (n=5), 5x LOD (n=3) and 100x LOD (n=2) by spiking SARS-
236 CoV-2 RNA into individual negative swab samples. All 35 negative samples were
237 negative and all 30 spiked positive samples were positive when tested with the
238 SAMBA II SARS-CoV-2 Test (Table 2). The overall sensitivity was 100% (95%CI:
239 88.43-100%) and specificity was 100% (95%CI: 90-100%).
240
241 **Clinical evaluation**
242 The clinical performance of the SAMBA II SARS-CoV-2 Test was further evaluated
243 with 172 combined nose and throat samples from symptomatic individuals provided
244 blinded by Public Health England (PHE), Cambridge. The samples were provided in
245 Viral Transport Medium (VTM) diluted 1:2 with SAMBA SCoV buffer. After initial testing
246 there were 87 concordant positives, 81 concordant negatives and 4 discrepant results
247 (3 SAMBA positive and one SAMBA negative) compared with the PHE Colindale
248 reference laboratory test (Table 3). The three SAMBA positive samples were repeat
249 positive by SAMBA and on retest by PHE they were found to be borderline positive
250 with high CT values for at least one of the target genes on the Colindale or Cambridge

251 (Wuhan) test (Table 4). The one SAMBA negative sample was negative on repeat by
252 SAMBA but was positive by PHE for RdRp using both the Cambridge (Wuhan) and
253 Colindale assays, with Ct values of 28.87 and 31.18 respectively (Table 4). Therefore,
254 there was just 1 discrepant sample after retest, a false negative for SAMBA (Table 5).
255 From this data set the SAMBA II SARS-CoV-2 Test has a sensitivity of 98.9% (95%
256 CI 94.03-99.97%), specificity of 100% (95% CI 95.55-100%), PPV of 100% and NPV
257 of 98.78% (92.02-99.82%) when compared to the PHE reference tests. The one
258 SAMBA false negative gave a high Ct value on the PHE test (>31), suggesting low
259 viral load, and it was diluted (1:2) for SAMBA testing, which may explain the false-
260 negative result.
261

262 **Discussion**

263 POC molecular tests for SARS-CoV-2, such as SAMBA II, are required to quickly
264 triage patients as centralised testing can take 2-5 days for results. In addition, POC
265 tests would be extremely useful for non-laboratory residential settings such as prisons,
266 immigration centres, nursing homes and rehabilitative centres. The people living in
267 such facilities tend to be vulnerable populations who are at a higher risk for adverse
268 outcome and for infection due to living in close proximity to others [18] and early
269 identification and implementation of increased infection control measures would
270 reduce spread amongst residents and staff. POC would also be extremely useful in
271 other situations where rapid and accurate results are required e.g organ donation,
272 hospital admissions and emergency surgery. POC molecular tests with rapid
273 turnaround, such as SAMBA II, will be essential not only during high rates of infection
274 but also as the country begins to end the lockdown period and localised outbreaks will
275 need to be managed quickly and efficiently.

276 Our data shows that the SAMBA II SARS-CoV-2 Test is equivalent to centralised
277 testing with excellent sensitivity and specificity. Samples are inactivated in the SAMBA
278 collection buffer and results are available within 86-101 minutes at the POC. High
279 sensitivity and specificity are essential for the appropriate triaging and treatment of
280 incoming patients. The assay has a limit of detection of 250 cp/mL, which is in-line
281 with that claimed by other commercial SARS-CoV-2 tests [19,20]. The specificity of
282 the SAMBA SARS-CoV-2 Test in clinical samples was 100% and the sensitivity was
283 98.9% compared to the centralised molecular testing by PHE. This data includes 3
284 positive samples detected by SAMBA that were original negative by centralised testing
285 indicating good sensitivity. Clinical evaluation by Zhen et al [21] comparing the
286 performance of Xpert® Xpress SARS-CoV-2 (Cepheid), ePlex® SARS-CoV-
287 2 (GenMark) and ID NOW™ COVID-19 (Abbott) showed limit of detection of 100
288 cp/mL, 1,000 cp/mL and 10,000 cp/mL and clinical agreement with the reference
289 standard of 98.3%, 91.4% and 87.7% respectively. In another study the Xpert system
290 has been shown to have good agreement with the reference test over a wide range of
291 Ct values, including low positives [22,23] with a positive agreement of 98.9% and
292 negative agreement of 92.0% compared to Roche cobas [22]. The Abbott ID NOW
293 has been shown to have a positive agreement of 73.9% (95% CI: 63.2-82.3%) and
294 negative agreement of 100% (95%CI: 92.9-100%) compared to the lab-based Roche
295 cobas system, with the majority of false negative samples being low viral load (>30 Ct
296 cycles by Roche cobas) [22]. Abbott have since modified the instructions for use to
297 remove the use of swab in transport medium as samples may become too dilute and
298 affect the sensitivity [24].
299 Potential limitations of this study include that the virus inactivation study was carried
300 out using a constructed pseudovirus rather than a SARS-CoV-2 or other coronavirus

301 due to availability. Also clinical samples were collected in VTM and diluted 1:2 in SCoV
302 buffer rather than collected directly into SCoV buffer, which may affect the sensitivity.
303
304
305 **Acknowledgements**
306 RKG is funded by Wellcome Senior Fellowship In Clinical Science award no WT108082AIA
307
308 **References**
309 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X,
310 Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H,
311 Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical
312 features of patients infected with 2019 novel coronavirus in Wuhan, China.
313 Lancet 395(10223):497-506.
314 2. COVID-19 Dashboard by the Center for Systems Science and Engineering
315 (CSSE) at John Hopkins University (JHU). ArcGIS. John Hopkins University.
316 (Accessed 18th May 2020).
317 3. https://www.worldometers.info/coronavirus/ (Accessed 18th May 2020).
318 4. World Health Organisation. 2020. WHO Director-General's opening remarks at
319 the media briefing on COVID-19 - 11 March 2020. Available from:
320 https://www.who.int/dg/speeches/detail/who-director-general-s-opening-
321 remarks-at-the-media-briefing-on-covid-19---11-march-2020. (Accessed 10th
322 May 2020)
323 5. https://coronavirus.data.gov.uk (Accessed 18th May 2020).
324 6. Grzelak L, Temman S, Plachais C, Grzelak L, Temmam S, Planchais C,
325 Demeret C, Huon C, Guivel F, Staropoli I, Chazal M, Dufloo J, Planas

326 D, Buchrieser J, Rajah MM, Robinot R, Porrot F, Albert M, Chen K,
327 Crescenzo B, Donati F, Anna F, Souque P, Gransagne M, Bellalou J,
328 Nowakowski M, Backovic M, Bouadma I, Le Fevre L, Le Hingrat
329 Q, Descamps D, Pourbaix A, Yazdanpanah Y, Tondeur L, Besombes C,
330 Ungeheuer M, Mellon G, Morel P, Rolland S, Rey F, Behillil S, Enouf
331 V, Lemaitre A, Creach M, Petres S, Escriou N, Charneau P, Fontanet A, Hoen
332 B, Bruel T, Eloit M, Mouquet H, Schwartz O, van der Werf S. 2020. SARS-
333 CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-
334 symptomatic individuals and blood donors. medRxiv
335 https://doi.org/10.1101/2020.04.21.20068858
336 7. Pan Y, Zhang D, Yang P, Poon LIM, Wang Q. 2020. Viral load of SARS-CoV-2
337 in clinical samples. The Lancet. 20(4):411-412.
338 8. Corman, VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker
339 T, Brnink S, Schneider J, Schmidt ML, Mulders DGJC, Haagmans BL, van der
340 Veer B, van den Brink S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon
341 M, Peirlis M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020.
342 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro
343 Surveill, 25(3) https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
344 9. Ritchie AV, Goel N, Sembongi H, Lehga J, Farleigh LE, Edemaga D,
345 Wisniewski CA, Lee HH.(2016. Performance evaluation of the point-of-care
346 SAMBA I and II HIV-1 Qual whole blood tests. J Virol Methods. Nov;237:143-
347 149.
348 10. Ondiek J, Namukaya Z, Mtapuri-Zinyowera S, Balkan S, Elbireer A, Ushiro
349 Lumb I, Kiyaga C, Goel N, Ritchie A, Ncube P, Omuomu K, Ndiege K,
350 Kekitiinwa A, Mangwanya D, Fowler MG, Nadala L, Lee H. 2017. Multi-

351 country validation of SAMBA – A novel molecular point-of-care test for HIV-1
352 detection in resource-limited setting. J Acquir Immune Defic Syndr. Oct
353 1;76(2):e52-e57.
354 11. Ritchie AV, Ushiro-Lumb I, Edemaga D, Joshi HA, De Ruiter A, Szumilin E,
355 Jendrulek I, McGuire M, Goel N, Sharma PI, Allain JP, Lee HH. 2014. SAMBA
356 HIV semiquantitative test, a new point-of-care viral-load-monitoring assay for
357 resource-limited settings. J Clin Microbiol. 52(9):3377-83.
358 12. Goel N, Ritchie AV, Mtapuri-Zinyowera S, Zeh C, Stepchenkova T, Lehga J,
359 De Ruiter A, Farleigh LE, Edemaga D, So R, Sembongi H, Wisniewski C,
360 Nadala L, Schito M, Lee H. 2017. Performance of the SAMBA I and II HIV-1
361 Semi-Q Tests for viral load monitoring at the point-of-care. J Virol Methods.
362 Jun;224:39-45.
363 13. Titchmarsh L, Zeh, C, Verpoort T, Allain, J-P and Lee, H.2015. Leukodepletion
364 as a Point-of-Care Method for Monitoring HIV-1 Viral Load in Whole Blood. J. Clin.
365 Microbiol.53(4):1080-1086.
366 14. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. 2017 Full
367 length HIV-1 Gag determines protease inhibitor susceptibility within *in*
368 *vitro* assays. AIDS. Jul17;24(11):1615-1655.
369 15. Sridhar S, Forrest S, Kean I, Young J, Scott JB, Maes M, Pereira-Dias J,
370 Parmar S, Routledge M, Rivett L, Dougan G, Weekes M, Curran M,
371 Goodfellow I, Baker S. 2020. A blueprint for the implementation of a
372 validated approach for the detection of SARS-Cov2 in clinical samples in
373 academic facilities. bioRxiv https://doi.org/10.1101/2020.04.14.041319

374 16. Public Health England. 2017. UK Standards for Microbiology
375 Investigations - Evaluations, validations and verifications of diagnostic tests.
376 Issue no. 5, 16 March 2017
377 17. UK Legislation. Human Tissue Act. 2004.
378 18. Infection Prevention and Control guidance for Long-Term Care Facilities in the
379 context of COVID-19: World Health Organisation. [updated 21 March 2020].
380 Available from: https://apps.who.int/iris/handle/10665/331508. (Accessed 11
381 May 2020).
382 19. FDA. 2020. Xpert® Xpress SARS-CoV-2 Instructions for Use, April 2020.
383 https://www.fda.gov/media/136314/download (Accessed 10 May 2020).
384 20. FDA. 2020. Biomerieux ARGENE® SARS-CoV-2 R Gene® Instructions for
385 Use, May 2020. https://www.fda.gov/media/137742/download (Accessed 10
386 May 2020).
387 21. Zhen W, Smith E, Manj R, Schron D, Berry GJ. (2020) Clinical Evaluation of
388 Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2. J. Clin.
389 Microbiol. Apr 24 DOI: 10.1128/JCM.00783-20
390 22. Smithgall MC, Scherberkova' I, Whittier S, Green DA (2020) Comparison of
391 Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid
392 Detection of SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.04.22.055327.
393 23. Moran A, Beavis KG, Matushek SM, Ciaglia C, Francios N, Tesic V, Love N.
394 2020. The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-
395 CoV-2 and Roche cobas SARS-CoV-2 Assays. J Clin Microbiol. Apr 17.
396 doi: 10.1128/JCM.00772-2
397 24. Abbott. 2020. ID NOW COVID-19 Technical Brief and Sample Type Labelling
398 Update. April 2020

399 **Figure 1. Viral inactivation as demonstrated by Luminescence from a VSV-G**

400 **pseudotyped reporter virus in descending concentrations of SAMBA Reagent**

401 **(SCoV Buffer).**



402
403
404
405 **Table 1. LOD of the SAMBA II SARS-CoV-2 Test**

Concentration SARS-CoV-2 RNA (cp/mL)	Number tested	Number positive	% positive
750	3	3	100
500	3	3	100
250	**20**	**20**	**100**
200	3	2	66.7
150	3	2	66.7
100	3	0	0

406

407 **Table 2. Clinical performance in 65 contrived clinical samples**

Concentration SARS-CoV-2 RNA (cp/mL)	Number tested	Number positive	% agreement (95% CI)
1-2x LOD	20	20	100% (86.1-100%)
≥3x LOD	10	10	100 % (74.1-100%)
Negative	35	0	100% (91.5-100%)

408 **Table 3. Clinical performance in 172 clinical samples compared to PHE**

409 **reference test (initial results)**

		PHE reference test	
		POSITIVE	**NEGATIVE**
SAMBA SARS-CoV-2	**POSITIVE**	87	3
Test	**NEGATIVE**	1	81

410

411 **Table 4. Discrepant analysis of 4 samples**

Sample ID	SAMBA		PHE Colindale assay RdRp		PHE Wuhan Cambridge assay		Final result
	Initial result	Repeat result	Initial (Ct)	Repeat (Ct)	RdRp (Ct)	E (Ct)	
1-25	NEG	NEG	POS (31.18)	Not tested	POS (28.87)	Not tested	POS
2-17	POS	POS	NEG	NEG	NEG	POS (34.99)	POS
2-25	POS	POS	NEG (36.58)	POS (33.62)	NEG	NEG	POS
2-38	POS	POS	NEG	NEG	POS (35.09)	POS (34.06)	POS

412

413

414

415

416 **Table 5. Clinical performance in 172 clinical samples compared to PHE**

417 **reference test (after retest)**

		PHE reference test	
		POSITIVE	**NEGATIVE**
SAMBA SARS-CoV-2	**POSITIVE**	90	0
Test	**NEGATIVE**	1	81

418